A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules

Int Immunopharmacol. 2021 Feb:91:107269. doi: 10.1016/j.intimp.2020.107269. Epub 2020 Dec 16.

Abstract

Parkinson's disease (PD) is a neurodegenerative disease with complicated pathogenesis. A novel bibenzyl compound 2-[4-hydroxy-3-(4-hydroxyphenyl)benzyl]-4-(4-hydroxyphenyl)phenol (20C) has been shown to have some neuroprotective effects, and its mechanism still needs further research. In this study, we used a 6-hydroxydopamine (6-OHDA)-induced PD rat model to evaluate the protective effect of 20C. Our study found that 20C could improve behavioral defects in 6-OHDA-lesion rats, decrease neuroinflammation and protect their DA neurons. It could inhibit the activity of inducible nitric oxide synthase (iNOS) induced by 6-OHDA, and lead to a decrease in the expression of nitrated-α-synuclein. When exposed to AMT-an inhibitor of iNOS, the nitrated-α-synuclein in PC12 decreased, and 20C demonstrated the same function on nitrated-α-synuclein as AMT. Besides, we also found that nitrated-α-synuclein was displayed in microglia. And 20C could decrease the expression of antigen-presenting molecule major histocompatibility complex I (MHC I) in dopamine (DA) neurons and MHC II in microglia induced by 6-OHDA. So, these imply that nitrated-α-synuclein might act as an endogenous antigen activating adaptive immunity, and the neuroprotection of 20C might be associated with inhibiting the activity of iNOS, decreasing the expression of the antigen molecule nitrated-α-synuclein and the antigen presenting molecule MHC. Our results indicated that inhibiting iNOS might be an effective strategy to protect neurons from oxidative stress.

Keywords: 20C; Adaptive immunity; Nitrated-α-synuclein; Parkinson's disease; iNOS.

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Bibenzyls / pharmacology*
  • Brain / drug effects*
  • Brain / immunology
  • Brain / metabolism
  • Brain / pathology
  • Cytokines / metabolism
  • Disease Models, Animal
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / immunology
  • Dopaminergic Neurons / metabolism
  • Dopaminergic Neurons / pathology
  • Endocytosis / drug effects
  • Enzyme Inhibitors / pharmacology
  • Inflammation Mediators / metabolism
  • Male
  • Microglia / drug effects*
  • Microglia / immunology
  • Microglia / metabolism
  • Neuroprotective Agents / pharmacology*
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidative Stress / drug effects
  • Oxidopamine
  • PC12 Cells
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / immunology
  • Parkinsonian Disorders / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction
  • alpha-Synuclein / metabolism

Substances

  • Antioxidants
  • Bibenzyls
  • Cytokines
  • Enzyme Inhibitors
  • Inflammation Mediators
  • Neuroprotective Agents
  • Snca protein, rat
  • alpha-Synuclein
  • Oxidopamine
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat